Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions

Journal of Controlled Release

Volumn 142, Issue 2, 2010, Pages 214-220

  Sasson, K ^a   Marcus, Y ^a   Lev Goldman, V ^a   Rubinraut, S ^a   Fridkin, M ^a   Shechter, Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Aminoglycosides; Exendin 4; Hydrolysable albumin binding probe; Insulin; Prolong acting prodrug

Indexed keywords

AMINOGLYCOSIDES; DERIVATIZATIONS; DESIGN AND APPLICATION; EXENDIN-4; GLUCOSE LEVEL; IN-VIVO; PHYSIOLOGICAL CONDITION; PRODRUGS; SPONTANEOUS HYDROLYSIS;

FLEXIBLE MANUFACTURING SYSTEMS; GLUCOSE; HYDROLYSIS; PEPTIDES; PROBES;

INSULIN;

2 SULFO 9 HYDROXYMETHYL 7 (AMINO 3 MALEIMIDOPROPIONATE)FLUORENE N HYDROXYSUCCINIMIDE; ALBUMIN; EXENDIN 4; GENTAMICIN; GLUCOSE; INSULIN; INSULIN DETEMIR; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CHEMICAL ENGINEERING; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG POTENCY; ESCHERICHIA COLI; GLUCOSE BLOOD LEVEL; HYDROLYSIS; IC 50; IN VIVO STUDY; LOW DRUG DOSE; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINO ACID SEQUENCE; ANIMALS; GLUCOSE; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; PRODRUGS; PROTEIN BINDING; RATS; SERUM ALBUMIN; VENOMS;

EID: 76749145092     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.10.028     Document Type: Article

References (27)

1. Goodman L., Gilman A.G. The pharmacological basis of therapeutics 1995, McGraw-Hill, New-York.
2. Taylor A., Granger D.N. Exchange of macromolecules across the microcirculation. Handbook of Physiology 1984, 467-520. American Physiological Society, Bethesda. E.M. Renkin, C.C. Michel (Eds.).
3. Carter D.C., Ho J.X. Structure of serum albumin. Advances in Protein Chemistry 1994, 153-203. Academic Press, Inc., San Diego, CA. V.N. Schumaker (Ed.).
4. Kurtzhals P., Haveland S., Jonassen I., Kiehr B., Larsen U.D., Ribel V., Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 1995, 312:725-731.
5. Kurtzhals P., Haveland S., Jonassen I., Kiehr B., Ribel U., Markussen J. Albumin binding and time action of acylated insulins in various species. J. Pharm. Sci. 1996, 85:304-308.
6. Kurtzhals P., Haveland S., Jonassen I.B., Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. 1997, 86:1365-1368.
7. Tsubery H., Mironchik M., Fridkin M., Shechter Y. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 2004, 279:38118-38124.
8. Peleg-Shulman T., Tsubery H., Mironchik M., Fridkin M., Schreiber G., Shechter Y. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J. Med. Chem. 2004, 47:4897-4904.
9. Shechter Y., Tsubery H., Mironchik M., Rubinstein M., Fridkin M. Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett. 2005, 579:2439-2444.
10. Shechter Y., Goldwaser I., Lavon I., Gershonov E., Mester B., Mironchik M., Patt L.P., Fridkin M. A new approach for prolonging the half-life of peptides, proteins and low-molecular-weigh drugs in vivo. Drugs Future 2001, 26:669-676.
11. Nesher M., Vachutinsky Y., Fridkin G., Schwarz Y., Sasson K., Fridkin M., Shechter Y., Lichtstein D. Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide. Biochonjugate. Chem. 2008, 19:342-348.
12. Shechter Y., Mironchik M., Saul A., Gershonov E., Patt L.-P., Sasson K., Tsubery H., Mester B., Kapitokovsky A., Rubinraut S., Vachutinski Y., Fridkin G., Fridkin M. New technologies to prolong life-time of peptide and protein drugs in vivo. Int. J. Pept. Res. Therap. 2007, 13:105-117.
13. Shechter Y., Morinchik M., Rubinraut S., Saul A., Tsubery H., Fridkin M. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin. Bioconjugate Chem. 2005, 16:913-920.
14. Hunter W.M., Greenwood F.C. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature (London) 1962, 194:495-496.
15. Rodbell M. Metabolism of isolated fat cells: effects of hormones on glucose metabolism and lipolysis. J. Biol. Chem. 1964, 239:375-380.
16. Moody A.J., Stan M., Gliemann J. A simple free fat cell bioassay for insulin. Horm. Metab. Res. 1974, 6:12-16.
17. Shechter Y., Tsubery H., Fridkin M. N-[(2-sulfo)-9-fluorenylmethoxycarbonyl)3 -gentamicin C1 is a Long-Acting Prodrug Derivative. J. Med. Chem 2002, 45:4264-4270.
18. Marcus Y., Sasson K., Fridkin M., Shechter Y. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin. J. Med. Chem. 2008, 51(14):4300-4305.
19. Peters T.J. The albumin molecule: its structure and chemical properties. All about albumin, Biochemistry, Genetics and medical applications 1996, 24-54. Academic Press, Inc., San Diego, CA.
20. Chaires J.B. Calorimetry and thermodynamics in drug design. Annu. Rev. Biophys. 2008, 37:135-151.
21. Markusen J., Havelund S., Kurtzhals P., Andersen A.S., Halstrøm E., Hasselager E., Larsen V.D., Ribbel U., Schafter L., Jonassen V.I. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996, 39:281-288.
22. Reed R.G., Gates T., Jn T. Peters, Albumin immobilizing on agarose as a tool for measuring ligand binding of proteins or peptides. Anal. Biochem. 1975, 69:361-371.
23. Wiseman T., Williston S., Brandts J.F. Rapid measurements of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 1989, 179:131-137.
24. Shechter Y., Morinchik M., Rubinraut S., Tsubery H., Sasson K., Marcus Y., Fridkin M. Reversible pegylation of insulin facilitates its prolonged action in vivo. Eur. J. Pharm. Biopharm. 2008, 70:19-28.
25. Shechter Y., Tsubery H., Fridkin M. Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats. Biochem. Biophys. Res. Commun. 2003, 307:315-321.
26. Shechter Y., Patt L., Schreiber G., Fridkin M. Prolonging the half-life of human interferon-2 In circulation: Design, preparation, and analysis of FMS7-interferon-2. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1212-1217.
27. Kahn C.R., Shechter Y. Insulin, oral hypoglycemic agents and pharmacology of the endocrine pancreas. Goodman and Gilman Handbook of Pharmacology 1990, 1463-1495. Pergamon Press, New York/Oxford. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).